Department of Anesthesiology and Pain Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, 110, Deokan-Ro, Gwangmyeong-Si, Gyeonggi-Do, Republic of Korea.
Department of Anesthesiology and Pain Medicine, National Medical Center, Seoul, 04564, Republic of Korea.
Sci Rep. 2024 Jul 11;14(1):16001. doi: 10.1038/s41598-024-66901-5.
The vulnerability during pregnancy has raised concerns about the potential impact of COVID-19 on obstetric anesthesia, an essential aspect of maternal care during cesarean section procedures. To evaluate the influence of COVID-19 infection on obstetric anesthesia during cesarean section, we analyzed the data from Korean National Health Insurance System (NHIS). This retrospective study utilized data from Korean NHIS. We included patients admitted with operation codes specific to cesarean section between January 1, 2020, and December 31, 2021. We classified patients into a COVID (+) group with a diagnosis code (U071) 30 days around surgery and a COVID (-) group without the code in the same period. The primary outcome was 30-day mortality that was defined as death within 30 days of admission due to any causes. Secondary outcomes were pulmonary complications (pneumonia, acute respiratory distress syndrome [ARDS], pulmonary thromboembolism [PTE], or unexpected postoperative mechanical ventilation), ICU admission, cardiac arrest, myocardial infarction [MI], other thromboembolic events, surgical site infection, sepsis, acute renal failure [ARF], and hepatic failure. Among 75,268 patients who underwent cesarean section, 107 had a COVID-19 diagnosis code, while 75,161 did not. After 1:4 propensity score matching (PSM), 535 patients were included in each group. 30-day mortality showed no significant differences between the two groups both before and after PSM. The COVID (+) group demonstrated significantly elevated rates of pneumonia, ARDS, PTE, and surgical site infection both before and after PSM. Hospital length of stay and admission costs were also significantly longer and higher, respectively, in the COVID (+) group before and after PSM. In subgroup analysis, no differences were observed in mortality and postoperative complications based on the anesthesia method after matching. COVID-19 infection is associated with increased rates of postoperative complications, including pneumonia, ARDS, PTE, surgical site infection, longer hospital stays, and increased admission costs, in patients who underwent cesarean section.
在妊娠期间,人们对 COVID-19 对产科麻醉的潜在影响感到担忧,产科麻醉是剖宫产手术中产妇护理的重要方面。为了评估 COVID-19 感染对剖宫产期间产科麻醉的影响,我们分析了韩国国家健康保险系统 (NHIS) 的数据。这项回顾性研究利用了韩国 NHIS 的数据。我们纳入了 2020 年 1 月 1 日至 2021 年 12 月 31 日期间因手术代码接受剖宫产的患者。我们将患者分为 COVID(+)组和 COVID(-)组。COVID(+)组的患者在手术前后 30 天有诊断代码(U071),而 COVID(-)组的患者在同一时期没有该代码。主要结局是 30 天死亡率,定义为因任何原因在入院后 30 天内死亡。次要结局包括肺部并发症(肺炎、急性呼吸窘迫综合征 [ARDS]、肺血栓栓塞 [PTE] 或意外术后机械通气)、重症监护病房(ICU)入院、心脏骤停、心肌梗死 [MI]、其他血栓栓塞事件、手术部位感染、脓毒症、急性肾衰竭 [ARF] 和肝功能衰竭。在 75268 名接受剖宫产的患者中,有 107 名患者有 COVID-19 诊断代码,而 75161 名患者没有。经过 1:4 倾向评分匹配(PSM)后,每组纳入 535 名患者。在匹配前后,两组患者的 30 天死亡率均无显著差异。COVID(+)组在匹配前后的肺炎、ARDS、PTE 和手术部位感染发生率均显著升高。匹配前后,COVID(+)组的住院时间和入院费用也分别显著延长和增加。在亚组分析中,在匹配后,根据麻醉方法,死亡率和术后并发症无差异。在接受剖宫产的患者中,COVID-19 感染与术后并发症(包括肺炎、ARDS、PTE、手术部位感染、住院时间延长和入院费用增加)发生率升高有关。